Canada: Intellectual Property Weekly Abstracts Alert (Week of July 25, 2011)

Last Updated: July 29 2011
Most Read Contributor in Canada, September 2016

Edited by Chantal Saunders and Beverley Moore


Failure to Reply in Good Faith not Basis to Challenge Issued Patent

Corlac Inc. et al. v. Weatherford Canada Ltd. et al.

The Appellants appealed the findings of the Judge that the patent was valid and infringed. Seven issues were raised on appeal: the Court of Appeal returned the issue of infringement of one claim to the Judge for redetermination and dismissed the remaining issues.

The Court of Appeal refused to interfere with the Judge's finding with respect to the issue of co-inventorship pursuant to section 53(1) of the Patent Act. In particular, the Court of Appeal agreed with the Judge that materiality is fact-specific, and the misstatement in this case was immaterial. The Court of Appeal agreed with the Judge that section 73(1)(a) of the Patent Act, abandonment by lack of good faith reply, applies only during the prosecution of patent applications, and is no longer is relevant once a patent issues. Section 53(1) governs misrepresentation in issued patents

Court Refuses to Allow Majority of Pleadings to Foreign Jurisdictions

Astrazeneca Canada Inc. v. Apotex Inc.

Drug: omeprazole

The Court heard the dispute between the parties as to whether certain amendments to the amended Statement of Defence and Counterclaim should be allowed. The Court allowed pleadings relating to a Korean action recited in U.S. decisions that the Plaintiffs put in play. However, pleadings requesting discovery relating to litigation in other foreign countries, pleadings alleging that as the plaintiffs did not assert claimsin the United States, they could not assert them in Canada, and pleadings alleging estoppel based on alleged contrary statements made by the Plaintiffs in the United States and Korean proceedings against other parties were not allowed.


Order of Prohibition Granted with Respect To Prodrug of Known Compound

Hoffmann-La Roche Limited v. Apotex Inc.

Drug: CELLCEPT mycophenolate mofetil

The two issues raised in this prohibition proceeding related to whether the claimed compound's utility was demonstrated or soundly predicted, and whether the claimed compound was obvious. The Court described the patent as relating to a prodrug of a known compound that could be used as an immunosuppressive drug but had limitations. The Court found that the utility of the invention was demonstrated as of the filing date. The Court further found that the utility was soundly predicted. Finally, the Court found that the claimed compound was not obvious.


Court Upholds Previous Rulings that a Final Action Must Contain All Issues

Bartley v. Commissioner of Patents

The Applicants brought judicial review of a decision of the Commissioner of Patents (Commissioner) and the Court allowed that judicial review. During the prosecution of the patent application, after numerous Office Actions, the Examiner issued a Final Action. The Applicant's Agent responded to this Final Action. Then, a Patent Appeal Board (Board) was constituted and had undisclosed discussions with the Examiner. Furthermore, the Examiner provided at least one memorandum to the Board with the Examiner's view as to the status of the application. The Board did not hold a hearing, but recommended that the Examiner's rejection be reversed and that the matter be returned to the Examiner to deal with the other "outstanding defects".

The Commissioner accepted these recommendations. These discussions and recommendations were made without input from the Applicant's Agent.

The Court reviewed the evidence put forward by the Commissioner and found that it did not support the argument that there were outstanding matters after the Final Action. Furthermore, the Court found that the Board's inquiries and recommendations as to the outstanding matters were unsatisfactory and lacking in due process. The Court also held that the Board acted contrary to Patent Rule 30(6) by failing to explicitly present the Applicant's Agents with the Board's view that there were outstanding matters and without clearly offering the Applicants an opportunity to be heard.

The Court then held that as in Belzberg, a Final Action is meant to be final and there is an obligation upon the Examiner to put everything on the table at that point. There is no provision to keep certain matters outstanding when a Final Action is issued. Furthermore, even if there were such a provision, this case fails to show that there were such outstanding matters. Since the application was returned to the Examiner having been reversed by the Commissioner, there are no grounds left for a further substantive requisition and allowance must follow as a consequence.

The Court held that the most appropriate action would be to allow the application and let the rest of the world challenge the validity of the patent if they wish.

Patent Appeal Board Finds No Double Patenting and that Monoclonal Antibody Claims are Sufficient When Target Polypeptide is Described

Commissioner's Decision 1307

The application related to human receptors for the platelet factor 4 superfamily antibodies. It was also the subject of a voluntary divisional. The final action raised issues of obviousness double patenting and lack of support for monoclonal antibodies.

The relevant claims at issue for the obviousness double patenting argument were a claim to an antibody capable of binding an isolated platelet factor 4 superfamily receptor and a claim to an isolated platelet factor 4 superfamily receptor polypeptide. The Board held that the subject matter in the claims does not reflect the same intended utility. Furthermore, the Court held that the claims were not obvious variations, modifications or combinations. Thus, the Board found no double patenting would exist.

The claims at issue in the rejection for lack of support related to antibodies and pharmaceutical compositions of antibodies as well as the use of antibodies as an anti-inflammatory agent. The Board considered the submissions of the parties and held that as of the laid open date of this application, the core steps for producing a monoclonal antibody were well known and reliable. Furthermore, the Board held that a person skilled in the art would not need to undertake considerable or protracted experimentation to make monoclonal antibodies capable of binding the particular polypeptides described in the figures. However, the Board did require limitation of the scope of the claims to an antibody capable of binding the particular polypeptides described.

Finally, the Board refused to allow the use claims. After conducting a sound prediction analysis,

the Board held that the factual basis in the specification would not lead a skilled person to conclude that blinding and/or blocking any one of the PF4AR polypeptides with a specific antibody would, on its own, necessary result in inhibition of inflammation.


Health Canada released a draft Guidance Document Part III: Consumer Information, Guidance Document: Product Monograph. The consultation period runs from July 21 to September 19, 2011.

Health Canada posted a Notice to Manufacturers/Sponsors of Nonprescription Drug Products: Emerging Regulatory Requirement for Non-Medicinal Ingredient Labelling

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.